Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NC525

Monoclonal antibody · Antagonist of leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) · developed by NextCure

Phase 1 Most advanced trial (none active)
NXTC Developer
1 Registered trials

What is NC525?

NC525 is a humanized IgG1 kappa monoclonal antibody that binds LAIR1, an immune inhibitory checkpoint receptor, and inhibits LAIR1-mediated survival signaling. It also induces antibody-dependent cellular cytotoxicity and phagocytosis. It is studied in relapsed or refractory acute myeloid leukemia, chronic myelomonocytic leukemia and myelodysplastic syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
leukocyte-associated immunoglobulin-like receptor 1 (LAIR1)
Mechanism
Antagonist of leukocyte-associated immunoglobulin-like receptor 1 (LAIR1)
Pathways
LAIR1-mediated survival signaling, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis
Therapy area
Oncology
Developer
NextCure, Inc. (NXTC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05787496 Phase 1 Relapsed or Refractory Acute Myeloid Leukemia Terminated NXTC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic LeukemiaRelapsed or Refractory Myelodysplastic Syndrome

Other drugs acting on LAIR1

More from NextCure

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.

Follow NXTC, the company behind NC525

See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NXTC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.